Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allergy Therapeutics ( (GB:AGY) ) just unveiled an announcement.
Allergy Therapeutics has granted new share options under its long-term incentive plan to key members of its management team, including CEO Manuel Llobet and CFO Shaun Furlong, as part of a strategy to drive long-term value creation and align leadership incentives with shareholder interests. The options, which vest over three years based on adjusted EBITDA and share price performance, increase total outstanding options to 365.2 million shares, or 5.95% of current issued share capital, underscoring the company’s use of performance-linked equity to support its future growth plans and maintain alignment with broader stakeholder outcomes.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, which poses significant risks. Despite strong technical indicators suggesting bullish momentum, the overbought condition may lead to a correction. The negative P/E ratio and lack of dividend yield further detract from the stock’s attractiveness.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company headquartered in the UK, focused on the treatment and diagnosis of allergic disorders. It develops and markets allergy immunotherapies, including aluminium-free products with potential disease-modifying effects, and sells proprietary and third-party treatments across nine major European markets and through distributors in a further four countries.
Average Trading Volume: 381,894
Technical Sentiment Signal: Buy
Current Market Cap: £712.4M
For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.